ꓟꓰꓣꓚꓗ ꓡꓰ ꓫꓬꓹ ꓓꓳ ꓩꓴ ꓡˍ ꓟ ꓗꓳ-ꓪꓰꓼ ꓠꓻ ꓫꓬꓹ ꓠꓯ ꓞꓲꓼ ꓝꓓꓮ ꓔꓳꓹ ꓙ

Merck ꓠꓯ ꓞꓲꓼ ꓫꓬꓹ ꓜꓴ ꓡꓰ ꓫꓬꓹ ꓓꓳ ꓩꓴ ꓡ ꓟ ꓗꓳ-ꓪꓰꓼ ꓠꓻ ꓫꓬꓹ ꓠꓯ ꓞꓲꓼ Molnupiravir ꓔꓯ 2021 ꓘꓳꓼ 12 ꓦ 23 ꓠꓬꓲ ꓕꓯ ꓴꓢꓮ ꓝꓓꓮ (ꓜꓽ ꓓꓴ ꓐꓰ ꓠꓯ ꓞꓲꓼ ꓗꓪꓽ ꓫꓵꓽ ꓜꓴ) ꓡꓰ ꓘꓳ ꓣꓴ ꓗꓷꓳ꓿

Pfizer ꓠꓯ ꓞꓲꓼ ꓫꓬꓹ ꓜꓴ ꓡꓰ ꓫꓬꓹ ꓓꓳ ꓡ ꓟ ꓗꓳ-ꓪꓰꓼ ꓠꓻ ꓫꓬꓹ ꓠꓯ ꓞꓲꓼ Paxlovid ꓔꓯ ꓥ ꓟꓲ ꓟꓲꓸ ꓙꓬꓽ ꓕꓲ ꓠꓬꓲ 2021 ꓘꓳꓼ 12 ꓦ 22 ꓠꓬꓲ ꓕꓯꓽ ꓝꓓꓮ ꓡꓰ ꓘꓳ ꓣꓴ ꓗꓷ ꓟ ꓥ ꓡꓳ꓿

Molnupiravir ꓠꓯ ꓞꓲꓼ ꓠꓬ Paxlovid ꓠꓯ ꓞꓲꓼ ꓔꓯ ꓔꓯꓺ ꓠꓬꓲ ꓠꓬ 3 ꓩꓴꓸ ꓕꓲ ꓩꓴꓸ ꓡꓰꓽ ꓢꓯꓼ ꓙꓳ ꓡꓳ ꓐꓰ ꓢꓪꓼ ꓟꓶ ꓔ ꓢꓲ꓾ ꓖꓳ ꓓꓱꓽ ꓡꓲꓽ ꓢꓴ ꓤ ꓟꓶꓼ ꓤꓼ ꓐꓴ ꓜꓽ ꓟꓽ ꓓ ꓐꓰ ꓢꓷꓸ ꓙ ꓟꓴ ꓙ ꓔ ꓡꓳ꓿